Literature DB >> 21717331

Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.

Tommaso Cai1, Sandra Mazzoli, Francesca Meacci, Vieri Boddi, Nicola Mondaini, Gianni Malossini, Riccardo Bartoletti.   

Abstract

Chronic bacterial prostatitis (CBP) is, usually, caused by uropathogens, especially gram-negative bacilli, although infection is sometimes due to Gram-positive and atypical microorganisms. A recent increasing in prevalence of Gram-positive strains has been reported. The aim of this study was to explore the epidemiological features and resistance rates in uropathogens isolated from CBP outpatients in last 10 years. All consecutive outpatients with demonstrated CBP attending a single Sexually Transmitted Disease centre from January 1997 and December 2008, were enrolled and underwent microbiological cultures in first void early morning urine, midstream urine, expressed prostatic secretion, and post prostate massage urine. Prevalence of different bacterial strains was stratified in four different periods: 1997-1999, 2000-2002, 2003-2005, 2006-2008. Any changes observed in epidemiological features and resistance rates in uropathogens over the whole study period have been analyzed. The present study has been planned, thus, as in vitro study. From 6,221 patients, 4,601 Gram-positive and 1,620 Gram-negative bacterial strains have been isolated. Enterococcus faecalis and Escherichia coli strains are the first and second frequent pathogens found, respectively. Significant differences between E. faecalis prevalence in the 1997-1999 and 2006-2008 periods were found. E. coli showed a significant difference between prevalence in 1997-1999 and 2006-2008 periods. Gram-positive organisms showed a decreasing of susceptibility to ciprofloxacin as well as Gram-negative strains, while a good susceptibility to the levofloxacin was evidenced. E. faecalis prevalence seemed to be raised in 2006-2008 periods. Moreover, a decreasing of activity of ciprofloxacin and a good activity profile of levofloxacin have been reported.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717331     DOI: 10.1007/s12275-011-0391-z

Source DB:  PubMed          Journal:  J Microbiol        ISSN: 1225-8873            Impact factor:   3.422


  27 in total

1.  EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU).

Authors:  K G Naber; B Bergman; M C Bishop; T E Bjerklund-Johansen; H Botto; B Lobel; F Jinenez Cruz; F P Selvaggi
Journal:  Eur Urol       Date:  2001-11       Impact factor: 20.096

2.  Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome.

Authors:  Anthony J Schaeffer
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

3.  Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications.

Authors:  Sandra Mazzoli
Journal:  FEMS Immunol Med Microbiol       Date:  2010-02-17

4.  Coryneform bacteria in semen of chronic prostatitis patients.

Authors:  Silver Türk; Paul Korrovits; Margus Punab; Reet Mändar
Journal:  Int J Androl       Date:  2006-11-29

5.  Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Javier Ena; Francisco Arjona; Carmen Martínez-Peinado; Maria Del Mar López-Perezagua; Concepción Amador
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

6.  Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis.

Authors:  J Curtis Nickel; Jim Xiang
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

Review 7.  Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia.

Authors:  J N Krieger
Journal:  Minerva Urol Nefrol       Date:  2004-06       Impact factor: 3.720

Review 8.  Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status.

Authors:  F M E Wagenlehner; T Diemer; K G Naber; W Weidner
Journal:  Andrologia       Date:  2008-04       Impact factor: 2.775

Review 9.  Chronic prostatitis: management strategies.

Authors:  Adam B Murphy; Amanda Macejko; Aisha Taylor; Robert B Nadler
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 10.  Prostatitis: Infection, neuromuscular disorder, or pain syndrome? Proper patient classification is key.

Authors:  Jeannette Potts; Richard E Payne
Journal:  Cleve Clin J Med       Date:  2007-05       Impact factor: 2.321

View more
  15 in total

Review 1.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

2.  Chronic bacterial prostatitis in men with spinal cord injury.

Authors:  Jörg Krebs; Peter Bartel; Jürgen Pannek
Journal:  World J Urol       Date:  2014-01-08       Impact factor: 4.226

3.  A comparison of monomicrobial versus polymicrobial Enterococcus faecalis bacteriuria in a French University Hospital.

Authors:  C Fourcade; L Canini; J-P Lavigne; A Sotto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-19       Impact factor: 3.267

4.  Salmonella prostatitis in a man with spinal cord injury.

Authors:  Jörg Krebs; Konrad Göcking; Jürgen Pannek
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

5.  The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study.

Authors:  Riccardo Bartoletti; Tommaso Cai; Gabriella Nesi; Sara Albanese; Francesca Meacci; Sandra Mazzoli; Kurt Naber
Journal:  World J Urol       Date:  2013-08-06       Impact factor: 4.226

6.  Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis.

Authors:  Ibai Los-Arcos; Carles Pigrau; Dolors Rodríguez-Pardo; Nuria Fernández-Hidalgo; Antonia Andreu; Nieves Larrosa; Benito Almirante
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

7.  Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice.

Authors:  Ju-Hee Han; Jong-Hwan Park; Bo-Yeon Kim; Seo-Na Chang; Tae-Hyoun Kim; Jae-Hak Park; Dong-Jae Kim
Journal:  J Vet Sci       Date:  2015-03-20       Impact factor: 1.672

8.  Antimicrobial Resistance Pattern in Enterococcus faecalis Strains Isolated From Expressed Prostatic Secretions of Patients With Chronic Bacterial Prostatitis.

Authors:  Yumi Seo; Gilho Lee
Journal:  Korean J Urol       Date:  2013-07-15

Review 9.  Nonsteroidal anti-inflammatory drugs and prostatic diseases.

Authors:  Hitoshi Ishiguro; Takashi Kawahara
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

10.  One, No One and One Hundred Thousand: Patterns of chronic prostatic inflammation and infection.

Authors:  Konstantinos Stamatiou; Evangelia Samara; Richard Nicolas Lacroix; Hippocrates Moschouris; Gianpaolo Perletti; Vittorio Magri
Journal:  Exp Ther Med       Date:  2021-07-07       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.